Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Psoriatic Arthritis Under HUMIRA (Adalimumab) in Routine Clinical Practice.

Trial Profile

Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Psoriatic Arthritis Under HUMIRA (Adalimumab) in Routine Clinical Practice.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2012

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ELAN
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 09 Aug 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 08 Nov 2011 Planned initiation date changed from 1 Oct 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
    • 06 Jul 2011 Planned initiation date changed from 1 May 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top